Nelipepimut S - SELLAS Life Sciences Group
Alternative Names: Cancer vaccine E75; Cancer vaccine E75 - Apthera; Cancer vaccine Her2/neu E75 - Apthera; E75; E75 peptide; E75/GM-CSF vaccine; NeuVax; NPSLatest Information Update: 15 Dec 2023
At a glance
- Originator Henry M. Jackson Foundation for the Advancement of Military Medicine; Uniformed Services University of the Health Sciences; University of Texas M. D. Anderson Cancer Center
- Developer Galena Biopharma; Sellas Life Sciences Group; University of Texas M. D. Anderson Cancer Center
- Class Antineoplastics; Cancer vaccines; Immunotherapies; Peptide vaccines
- Mechanism of Action CD8 positive T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued Bladder cancer; Breast cancer; Gastric cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer
Most Recent Events
- 16 Mar 2023 Discontinued - Phase-I for Gastric cancer in USA (Intradermal)
- 16 Mar 2023 Discontinued - Phase-II for Breast cancer (Combination therapy, Neoadjuvant therapy) in USA (Intradermal)
- 16 Mar 2023 Discontinued - Phase-III for Breast cancer (Early-stage disease, Prevention of relapse, Adjuvant therapy) in Bulgaria (Intradermal)